世界首例基因編輯嬰兒事件的科學與倫理學思考
Scientific and Ethical Thinking about the World's First Gene-edited Infant Event
DOI:
https://doi.org/10.24112/ijccpm.171665Keywords:
CRISPR/Cas9技術, CCR5, 基因編輯, 人類胚胎, 生物醫學研究倫理Abstract
LANGUAGE NOTE | Document text in Chinese; abstract also in English.
南方科技大學賀建奎博士 2018年11月26曰宣佈一對基因編輯嬰兒於11月在中國健康誕生為背景,分析了使用CRISPR/Cas9基因編辑技術以及選擇CCR5作為抵抗愛滋病感染靶標存在的科學和倫理學問題,探討了相關研究可能對人類遺傳物質造成不可逆轉的改造,進而混入人類的基因庫具有巨大風險和倫理爭議。因此,現階段應對基因編辑相關研究加強規範和監管,在技術尚不成熟的情況下,不能隨意開展人類生殖細胞和人類胚胎基因編辑研究,更不能質然推廣到臨床研究。
This study is based on the announcement by Dr. He Jiankui of Southern University of Science and Technology on November 26, 2018 that a pair of gene-edited babies were born in China in November. It discusses the ethical problems posed by Dr. He's research in CRISPR-based gene editing technology for human embryos, analyzes the scientific and ethical problems in CRISPR/Cas9 technology and choosing CCR5 as the target of anti-AIDS infection, and investigates the feasibility of relevant research. The fact that human genetic material can be irreversibly transformed into a human gene pool presents a huge risk and an ethical controversy. Therefore, we should strengthen the regulation and supervision of gene editing research at this stage. In this immature phase of technology development, we cannot conduct gene editing research with human germ cells and human embryos at will, especially clinical research.
DOWNLOAD HISTORY | This article has been downloaded 100 times in Digital Commons before migrating into this platform.
Downloads
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2019 International Journal of Chinese & Comparative Philosophy of Medicine
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The CC BY-NC 4.0 license permits use, distribution and reproduction in any medium, provided the original work is properly cited and not used for commercial purposes. Copyright on any article is retained by the author(s) and the publisher(s).